In ₹ Crore except Per Share Latest Annual	PARNAXLAB FY25	BPLPHARMA FY23	JENBURPH FY26	KPL FY24	Peer Average
Valuation — at last close
P/E	85.54×	◆ 40.46×	—	—	40.46× +111%
P/B	—	5.15×	—	—	5.15×
EV/EBITDA	—	46.06×	—	—	46.06×
Market Cap	—	₹985 Cr	—	—	₹985 Cr
Growth
Revenue CAGR 3Y	-0.61%	—	◆ 7.26%	—	7.26% -108%
Revenue CAGR 5Y	-1.78%	—	◆ 9.07%	—	9.07% -120%
Net Income CAGR 3Y	—	—	12.18%	—	12.18%
Profitability
EBITDA Margin	17.61%	9.80%	◆ 23.81%	21.69%	18.43% -4%
Net Income Margin	—	11.16%	◆ 20.59%	—	15.88%
Return on Common Equity	—	13.63%	◆ 18.84%	—	16.23%
Return on Capital Employed	—	—	—	19.78%	19.78%
Return on Assets	—	9.25%	◆ 16.45%	—	12.85%
Credit & Quality
Total Debt/Equity	—	◆ 0.04×	—	0.43×	0.23×
Interest Coverage	◆ 49.06×	7.10×	—	4.54×	5.82× +743%
Scale — latest FY
Revenue / Total Income	₹7 Cr	₹218 Cr	₹169 Cr	₹307 Cr	₹231 Cr -97%
Net Income	—	₹24.3 Cr	₹34.7 Cr	—	₹29.5 Cr
Total Assets	₹24.7 Cr	₹308 Cr	₹226 Cr	₹398 Cr	₹311 Cr -92%
EPS	₹1.21	₹42.14	—	—	₹42.14 -97%
Book Value per Share	—	₹330.83	—	—	₹330.83

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.